

Detection in subsequent screen round in the Netherlands: results for two FIT cut-off levels

Arthur Kooyker

On behalf of the national monitoring and evaluation team



Possible conflicts of interest

- None



Aim

- Present yield and participation in the second round of the Dutch CRC screening program for populations with different screening histories



Dutch CRC Screening Program

- Initiation: 2014
- Screening modality: FIT
- Interval: Biennial
- Target group: 55 – 75 years old
- Roll-out period: 5 years




First round


- Real-time monitoring
 - Higher than expected positivity rate
 - Lower than expected FIT positive predictive value
- Increased FIT cut-off level from 15 μg to 47 μg Hb per gram of feces




First round



First round



First round




Age-adjusted; AN = Advanced Neoplasia

Toes-Zoutendijk, 2017, Gastroenterology



Second round




Second round: participation


- Participation rates:
 - Total: 75.9%
 - Repeated participation: 93.4%
 - Previous non-participants: 21%



Second round



Second round: repeated participation



Age-adjusted; AN = Advanced Neoplasia




Second round: repeated participation


- Correlation between amount of Hemoglobin in the feces and outcomes in subsequent round



Second round: repeated participation



Second round: repeated participation




Second round: previous non-participants


- 21% of the non-participants of the first round participated in the second round



Second round



Second round: previous non-participants



Not age-adjusted; AN = Advanced Neoplasia

Toes-Zoutendijk, 2017, Gastroenterology

Arthur Kooyker



Conclusion

- When FIT is repeated, most of the missed findings due to a higher FIT cut-off level are detected in the subsequent round
- Strong correlation between FIT results in the first round and outcomes in the subsequent round
- Previous non-participants are at higher risk of developing advanced neoplasia



Thank you for your attention

On behalf of the national monitoring and evaluation team
(LECO):

Iris Lansdorp-Vogelaar, Esther Toes, Monique van Leerdam, Evelien Dekker, Maaïke Buskermolen, Iris Nagtegaal, Anneke van Vuuren, Ernst Kuipers, Loes van Velthuysen, Maarten Thomeer, Harriët van Veldhuizen, Chris Ramakers, Folkert van Kemenade, Harry de Koning, Manon Spaander

a.kooyker@erasmusmc.nl

